(Gly21)-Amyloid beta-Protein (1-40) is a modified form of the amyloid-beta peptide, critical in the study of Alzheimer's disease. The glycine substitution at position 21 alters the peptide's aggregation properties, which is essential for investigating amyloid plaque formation and neurodegenerative processes. This compound is widely used in research on Alzheimer's disease pathophysiology and therapeutic interventions targeting amyloid-beta.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More